John Hamm

Norton Healthcare — United States

Medicine · Health Sciences

25h-index7.6kcitations118works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(16), Lung Cancer Research Studies(15), Cancer Immunotherapy and Biomarkers(13), Lung Cancer Treatments and Mutations(13), Colorectal Cancer Treatments and Studies(13)

Publications118 total

A phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).
Journal of Clinical Oncology·2026
1344 AgenT-797, an allogeneic iNKT cell therapy, demonstrates durable clinical activity in solid tumors: updated phase 1 findings
2025Open Access
P3.18.39 PRESERVE-003: A Phase 3 Study of Gotistobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors
Journal of Thoracic Oncology·2025
OS03-09 Surveying the Landscape: A Modular Generative Artificial Intelligence Workflow to Identify NAMs for Systemic Toxicity
Toxicology Letters·2025Open Access
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Journal of Clinical Oncology·2025· 20 citedOpen Access
Enhancing lung cancer surgical quality: Insights from a national quality improvement collaborative.
Journal of Clinical Oncology·2025
Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.
Journal of Clinical Oncology·2025
Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab
Future Science OA·2024Open Access
Strengthening vaccination assessment at a southern oncology center: A quality improvement endeavor.
JCO Oncology Practice·2024· 1 cited
1211P IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
Annals of Oncology·2024· 8 citedOpen Access
Crosstalk of glutamine metabolism and NFATc1 – unfolding vulnerabilities for enhanced therapeutic efficacy in PDAC
Zeitschrift für Gastroenterologie·2024Open Access
Autoimmune pancreatitis—New evidence for clinical management strategies
United European Gastroenterology Journal·2024Open Access
MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC
Journal of Thoracic Oncology·2023· 5 citedOpen Access
735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer
Regular and Young Investigator Award Abstracts·2023· 3 citedOpen Access
742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors
Regular and Young Investigator Award Abstracts·2023· 4 citedOpen Access
599 Single-agent safety and activities of target-preserving anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) in PD-(L)1 resistant metastatic NSCLC and population PK analysis in patients with solid tumors
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Journal of Clinical Oncology·2023· 273 cited
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
Journal for ImmunoTherapy of Cancer·2023· 14 citedOpen Access
NFATc1 in hypoxia and glutamine-deficiency dependent metabolic reprogramming of pancreatic cancer
Zeitschrift für Gastroenterologie·2023Open Access
page 1 of 6Next →

Frequent Co-authors

Donald Richards(6), John L. Villano(5), Enriqueta Felip(4), J. Randolph Hecht(3), Louis Fehrenbacher(3), D. Lawrence Wickerham(3), Norman Wolmark(3), Christina Tsien(3), Adam P. Dicker(3), Jeffrey J. Raizer(3), M.M. Matuszak(3), Enrico C. Lallana(3), Jiayi Huang(3), Özer Algan(3), Lorraine Portelance(3), Kevin Oh(3), Arif N. Ali(3), Scott Lindhorst(3), Minesh P. Mehta(3), Tomislav Dragovich(3)